About the
ABILIFY MYCITE® System

The first FDA-approved digital medicine system
captures robust objective and patient-reported
data to help inform treatment plans and
facilitate communication.1

ABILIFY MYCITE® (aripiprazole tablets with sensor)
has not been shown to improve patient
compliance or for use in modifying aripiprazole
dosage. It should not be used in “real-time” or
during an emergency, because detection may be
delayed or not occur.

What the
ABILIFY MYCITE System does

Use data-driven insights captured by the ABILIFY MYCITE System to help inform treatment decisions.1

The system combines wearable and ingestible sensors, smartphone technology, and patient-reported experiences to help empower you, your patients, and their support network to better understand how your patients are doing between visits.1

Objective medication ingestion data1

Objective Medication Ingestion Data, Icon, Objective Medication Ingestion Data: Recorded Ingestion Date & Time, Icon

Date and time of ingestion of
ABILIFY MYCITE®
(aripiprazole tablets with sensor)

Objective Medication Ingestion Data, Icon, Objective Medication Ingestion Data: Recorded Ingestion Date & Time, Icon

Date and time of ingestion of ABILIFY MYCITE® (aripiprazole tablets with sensor)

Objective physiological data1

Activity
Objective Physiological Data: Activity, Icon

Steps taken and
miles walked
every 24 hours

Rest
Objective Physiological Data: Rest, Icon, Objective Physiological Data: Resting Time, Icon

Extended periods of time when a patient’s body is resting in a flat position up to an angle of 30°

Patient-reported data1

Mood
Patient Reported Data: Mood, Icon
Rest quality
Patient Reported Data: Rest Quality, Icon

Self-reported data, including mood, based on a 7-point visual scale, and quality of rest, based on a 5-point visual scale

Mood Rest Quality
Patient Reported Data: Mood, Icon, Objective Physiological Data: Rest, Icon

Self-reported data, including mood, based on a 7-point visual scale, and quality of rest, based on a 5-point visual scale

Reason for a
missed dose
Patient Reported Data: Reason For Missed Dose, Icon

Self-reported reasons for missing a dose, such as:

  • I didn't feel like it
  • I forgot
  • I couldn't
  • I took it after midnight
  • I took my tablet but it did not register on the app
Reason for a
missed dose
Patient Reported Data: Reason For Missed Dose, Icon

Self-reported reasons for missing a dose, such as:

  • I didn't feel like it
  • I forgot
  • I couldn't
  • I took it after midnight
  • I took my tablet but it did not register on the app

Although most ingestions will be detected within 30 minutes, it may take up to two hours to detect the ingestion of ABILIFY MYCITE; in some cases, tablet ingestion may not be detected. If this occurs, patients should be told not to repeat the dose.

Only functions related to tracking drug ingestion have been evaluated or approved by FDA.

Visibility into your patients’ medication-taking patterns and other data may help you2‑4­:

Identify factors contributing 
to nonadherence

Assess treatment response,
if adherent

Personalize
treatment strategies

Strengthen the
therapeutic alliance

Foster a
more open dialogue

Engage and
empower patients

The impact of the ABILIFY MYCITE System on treatment adherence has not been demonstrated. Some factors, such as connectivity, transmitter malfunction, or device availability, may impact the consistency and reliability of data detection, collection and transmission. Only functions related to tracking drug ingestion have been evaluated or approved by FDA.

Comprehensive data,
all in one place

The MYCITE® Dashboard uses the data captured by the ABILIFY MYCITE System to provide you with a more holistic view of your patients.3

MYCITE® Dashboard: Comprehensive Data All In One Place

Review daily ingestion data

See mood each day

See rest and patient-reported rest quality

See activity level

Illustrative data. Not from a real patient.

With the MYCITE Dashboard,
you can1:

  • View daily ingestion data at your discretion
  • Review daily, weekly, or monthly activity and patient-reported rest and mood
  • Choose to set up alerts for multiple missed or consecutively missed doses
  • Align on patient status with other care team members

Your patients may have multiple care team members. Together, you can use the ABILIFY MYCITE System to get a common view of patient data.1

Would your patients benefit
from the ABILIFY MYCITE System?

Learn More

Not a real patient.
How ABILIFY MYCITE® System Works, Icon

How the ABILIFY MYCITE System works

A smart pill combined with a wearable Bluetooth®* patch captures medication ingestion and objective physiological data, presented in the MYCITE Dashboard alongside patient-reported data.1

*Bluetooth is a registered trademark of Bluetooth SIG, Inc.

The components of the
ABILIFY MYCITE System
include:

Not actual size.
ABILIFY MYCITE® Pill

ABILIFY MYCITE Pill

Each aripiprazole tablet is manufactured with an integrated sensor that sends a signal to the MYCITE® Patch after ingestion.1

Not actual size.
MYCITE® Patch

MYCITE Patch

A nonmedicated, wearable sensor that receives the ingestion signal from the pill and logs specific physiological data, such as activity level and rest. Data are sent via Bluetooth®* to the MYCITE® App.

MYCITE® App Mood Rating Screenshot

MYCITE App

A smartphone application for the patient to review their medication ingestion data, daily activity level, and to report and share their rest quality, mood, and reason for missing a dose.

MYCITE® Dashboard Weekly View Screenshot

MYCITE Dashboard

An online portal for healthcare providers and the patient's support network that displays a summary of medication ingestion, physiological data, and patient-reported data over time.

ABILIFY MYCITE® Conversation With Your Patients

A conversation

Equipped with the data delivered to you by the ABILIFY MYCITE System, you, your patients, and their care team and support network can have more-informed conversations about the patient's mental health and treatment plan.1

The impact of the ABILIFY MYCITE System on treatment adherence has not been demonstrated. Some factors, such as connectivity, transmitter malfunction, or device availability, may impact the consistency and reliability of data detection, collection and transmission. Only functions related to tracking drug ingestion have been evaluated or approved by FDA.

Your patients’ information is secure

Your Pateints' Information Is Secure

The ABILIFY MYCITE System encrypts all data and stores them in the cloud to protect patient information at all times.

Once the system is set up by the patient, the patient can choose whom they want to share their information with. As their healthcare provider, you will see the same information that your patient sees.1

This can be their1:

Family members
Friends
Case manager
Nurse practitioner
Primary care provider
Psychiatrist
Psychologist
Social worker
Therapist

This can be their1:

  • Family members
  • Friends
  • Case manager
  • Nurse practitioner
  • Primary care provider
  • Psychiatrist
  • Psychologist
  • Social worker
  • Therapist
Your Pateints' Information Is Secure

The privacy of the patients’ personal information shared through the ABILIFY MYCITE System is important. Only those chosen by the patient may view their information, and the patient may choose to stop sharing their information at any time.Info

A connected-care system for you, your patients, and those who care for them1

With the ABILIFY MYCITE System, you and your patients will have medication ingestion data at your fingertips. If patients choose, they can also give people in their support network access to information about their mood, rest, and reasons why they did not take their medication.

When everyone is working with the same information, it can help reduce uncertainty and foster trust.
 

Want to talk to an 
Otsuka representative?

Get in touch

Talk To An Otsuka Representative, Icon

References

1. Otsuka and Proteus® announce the first U.S. FDA approval of a digital medicine system: ABILIFY MYCITE® (aripiprazole tablets with sensor) [press release]. Tokyo, Japan, and Redwood City, CA; November 14, 2017. https://www.otsuka-us.com/discover/articles-1075. Accessed September 19, 2019. 2. Hatch A, Docherty JP, Carpenter D, Ross R, Weiden PJ. Expert consensus survey on medication adherence in psychiatric patients and use of a digital medicine system. J Clin Psychiatry. 2017;78(7):e803-e812. 3. Shafrin J, May SG, Shrestha A, et al. Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers. Patient Prefer Adherence. 2017;11:1071-1081. 4. Elenko E, Underwood L, Zohar D. Defining digital medicine. Nat Biotechnol. 2015;33(5):456-461.

For more information about the system’s privacy requirements, please review the
ABILIFY MYCITE System Terms of Use, Privacy Notice, and Authorization & Consent.